| Literature DB >> 23782465 |
Stefanie Verherstraeten1, Evy Goossens, Bonnie Valgaeren, Bart Pardon, Leen Timbermont, Karen Vermeulen, Stijn Schauvliege, Freddy Haesebrouck, Richard Ducatelle, Piet Deprez, Filip Van Immerseel.
Abstract
Bovine necrohemorrhagic enteritis is a major cause of mortality in veal calves. Clostridium perfringens is considered as the causative agent, but there has been controversy on the toxins responsible for the disease. Recently, it has been demonstrated that a variety of C. perfringens type A strains can induce necrohemorrhagic lesions in a calf intestinal loop assay. These results put forward alpha toxin and perfringolysin as potential causative toxins, since both are produced by all C. perfringens type A strains. The importance of perfringolysin in the pathogenesis of bovine necrohemorrhagic enteritis has not been studied before. Therefore, the objective of the current study was to evaluate the role of perfringolysin in the development of necrohemorrhagic enteritis lesions in calves and its synergism with alpha toxin. A perfringolysin-deficient mutant, an alpha toxin-deficient mutant and a perfringolysin alpha toxin double mutant were less able to induce necrosis in a calf intestinal loop assay as compared to the wild-type strain. Only complementation with both toxins could restore the activity to that of the wild-type. In addition, perfringolysin and alpha toxin had a synergistic cytotoxic effect on bovine endothelial cells. This endothelial cell damage potentially explains why capillary hemorrhages are an initial step in the development of bovine necrohemorrhagic enteritis. Taken together, our results show that perfringolysin acts synergistically with alpha toxin in the development of necrohemorrhagic enteritis in a calf intestinal loop model and we hypothesize that both toxins act by targeting the endothelial cells.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23782465 PMCID: PMC3722007 DOI: 10.1186/1297-9716-44-45
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Description of strains and toxin activities in supernatants of an overnight culture
| Wild-type | JIR325 | Strain 13d | | 12.5 ± 2.5 | 4.8 ± 0.2 | [ |
| Δ | JIR4444 | JIR325 pfoA::ermB plcΩpJIR1774, suicide plasmid | | < 1.0 | < 1.0 | [ |
| JIR4460 | JIR4444(pJIR871), CmR | < 1.0 | 4.1 ± 0.3 | [ | ||
| JIR4461 | JIR4444(pJIR1642), CmR | 6.8 ± 0.7 | < 1.0 | [ | ||
| double-complemented Δ | JIR4462 | JIR4444(pJIR1720), CmR | 8.0 ± 0.5 | 3.5 ± 0.1 | [ |
apfoA: perfringolysin gene, plc : alpha toxin gene, Cmr: chloramphenicol resistant, Plc : alpha toxin, PFO: perfringolysin O, dJIR325 is a rifampicin and nalidixic acid resistant derivative of strain 13, a gas gangrene strain.
Figure 1Histological section from an intestinal loop inoculated with wild-type. Hematoxylin and eosin stained histological section from an intestinal loop inoculated with a logarithmic culture of the wild-type strain and milk replacer, sampled after 6 h incubation. Arrows indicate the demarcation of the necrosis of the villus tip with loss of epithelial cells. Also capillary congestion (1) and hemorrhage (2) are present.
Figure 2Number of loops with necrosis for wild-type and isogenic mutants. The graph shows the total number of loops in which necrosis was present, evaluated 6 h after inoculation with a logarithmic-phase culture of the wild-type strain (WT), ΔpfoA Δplc mutant (ΔpfoA Δplc), pfoA-complemented ΔpfoA Δplc mutant (pfoA-c.), plc-complemented ΔpfoA Δplc mutant (plc-c.), double-complemented ΔpfoA Δplc mutant (double-c.) and BHI as a control in three calf intestinal loop assays. Each strain was inoculated in quintuplicate. A significant difference was found between the wild-type and the ΔpfoA Δplc double mutant (P < 0.01) and the pfoA-complemented ΔpfoA Δplc mutant (P < 0.01).
Figure 3Cytotoxic effect of the supernatant of wild-type and isogenic mutants on bovine umbilical vein endothelial cells (BUVEC.) Photomicrograph of Haemacolor-stained cells after 1.5 h exposure to 3% supernatant of the wild-type strain (WT), ΔpfoA Δplc double mutant (ΔpfoA Δplc), pfoA-complemented ΔpfoA Δplc mutant (pfoA-c.), plc-complemented ΔpfoA Δplc mutant (plc-c.), double-complemented ΔpfoA Δplc mutant (double-c.) and SFM as a negative control. Magnification, ×400.
Figure 4Effect of the supernatant of wild-type and isogenic mutants on the viability of bovine umbilical vein endothelial cells. The graph shows the percentage of viable cells relative to viable untreated cells (negative control) and cells treated with supernatant of the wild-type strain (positive control) after 1.5 h incubation with 6 and 1% supernatant of ΔpfoA Δplc double mutant (ΔpfoA Δplc), pfoA-complemented ΔpfoA Δplc mutant (pfoA-c.), plc-complemented ΔpfoA Δplc mutant (plc-c.) and double-complemented ΔpfoA Δplc mutant (double-c.). The values are the average of three independent experiments conducted in duplicate with error bars representing the standard deviations (SD). Asterisks indicate significant difference between that strain and all other strains for each concentration (p < 0.001).